Amgen, Astellas sales and marketing update

Astellas and Amgen Astellas BioPharma K.K. launched Repatha evolocumab in Japan to treat familial hypercholesterolemia and hypercholesterolemia in patients who have a high risk of cardiovascular events and do not adequately respond to statins. The National Health Insurance (NHI) price of a 140 mg syringe of Repatha is Y22,948 ($206.53). Patients receive 420 mg Repatha every four weeks. Amgen said Repatha is the first PCSK9 inhibitor available in Japan. ...